GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aspira Womens Health Inc (NAS:AWH) » Definitions » Probability of Financial Distress (%)

Aspira Womens Health (Aspira Womens Health) Probability of Financial Distress (%) : 1.85% (As of May. 16, 2024)


View and export this data going back to 2000. Start your Free Trial

What is Aspira Womens Health Probability of Financial Distress (%)?

Probability of Financial Distress (%) measures the probability that a company will go bankrupt in the upcoming year given its current financial position. A higher ratio indicates a larger probability of bankruptcy for the company, while a lower ratio indicates a healthier fundamental. As of today, Aspira Womens Health's Probability of Financial Distress (%) is 1.85%.

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Competitive Comparison of Aspira Womens Health's Probability of Financial Distress (%)

For the Diagnostics & Research subindustry, Aspira Womens Health's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aspira Womens Health's Probability of Financial Distress (%) Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aspira Womens Health's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Aspira Womens Health's Probability of Financial Distress (%) falls into.



Aspira Womens Health Probability of Financial Distress (%) Calculation

Probability of Financial Distress (%) (PFD) was developed by John Campbell, Jens Hilscher and Jan Szilagyi in their Search of Distress Risk. It measures the probability that a company will go bankrupt within the next 12 months given its current financial position.

The Probability of Financial Distress (%) was obtained by a logit probability model based on eight explanatory variables. The logit formula to compute the probability of financial distress (LPFD) is given below:

LPFD= -20.12 * NIMTAAVG + 1.60 * TLMTA - 7.88 * EXRETAVG + 1.55 * SIGMA - 0.005 * RSIZE - 2.27 * CASHMTA + 0.070 * MB - 0.09 * PRICE -8.87
=-3.97

The Probability of Financial Distress (%) (PFD) was then obtianed by:

PFD=1/(1 + e^(-LPFD))*100%
=1.85%

The eight explanatory variables are:

1. NIMTAAVG = Net Income to Market Total Assets

NIMTAAVG=Net Income / Market Total Assets
=Net Income / (Market Cap + Total Liabilities)

*Note that for companies reported quarterly, geometrically declining weighted quarterly Net Income data in latest four quarters are used.

2. TLMTA = Total liabilities to Market Total Assets

TLMTA=Total Liabilities / Market Total Assets

3. CASHMTA = Cash to Market Total Assets

For non-financial companies, CASHMTA is measured as:

CASHMTA=Cash, Cash Equivalents, Marketable Securities / Market Total Assets

4. EXRETAVG = Excess Return compared to the S&P 500

EXRETAVG is the weighted excess return compared to the S&P 500 in past 12 month. Geometrically declining weights are imposed on the monthly excess return to reflect lagged information. The weight is halved each quarter.

5. SIGMA = Standard Deviation of Daily Returns

For sigma, we use the annualized standard deviation of a company's returns over the past 92 days (or 63 trading days).

6. RSIZE = Relative Size

RSIZE=log (Market Cap / Total Market Cap of S&P 500 companies)

7. MB = Market to Adjusted Book Equity Ratio


8. PRICE

PRICE is measured as the log of the stock price, capped at log(15).


Aspira Womens Health  (NAS:AWH) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.


Aspira Womens Health Probability of Financial Distress (%) Related Terms

Thank you for viewing the detailed overview of Aspira Womens Health's Probability of Financial Distress (%) provided by GuruFocus.com. Please click on the following links to see related term pages.


Aspira Womens Health (Aspira Womens Health) Business Description

Traded in Other Exchanges
N/A
Address
12117 Bee Caves Road, Suite 100, Building 3, Austin, TX, USA, 78738
Aspira Womens Health Inc is engaged in developing and commercializing diagnostic tests for gynecologic diseases. The Company markets and sells, 1) Ova1, a blood test intended as an aid to assess the likelihood of malignancy in women with an ovarian adnexal mass for which surgery is planned when the physician's independent clinical and radiological evaluation does not indicate malignancy; (2) Overa, a second-generation biomarker reflex intended to maintain Ova1's high sensitivity while improving specificity; (3) Ova1Plus, a reflex offering which uses Ova1 as the primary test and Overa as a confirmation for Ova1 intermediate range results; and (4) OvaWatch, a lab-developed blood test intended to assist in the initial clinical assessment of malignancy risk in all women with an adnexal mass.
Executives
Nicole Sandford director 12117 BEE CAVES RD BLDG 3, STE 100, AUSTIN TX 78738
Minh Hoang Merchant officer: General Counsel & Secretary 1210 AVONDALE ROAD, HILLSBOROUGH CA 94010
Torsten Hombeck officer: Chief Financial Officer 529 W 42ND ST #6V, NEW YORK NY 10036
Celeste Rachelle Fralick director 2801 MESA ROAD, LUBBOCK TX 79403
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Stefanie L. Cavanaugh director 1120 S CAPITAL OF TX HWY, BLDG 1, STE 300, AUSTIN TX 78746
Ellen O'connor Vos director C/O NTELOS HOLDINGS CORP., 1154 SHENANDOAH VILLAGE DRIVE, WAYNESBORO VA 22980
Jack W Schuler 10 percent owner 100 N. FIELD DRIVE, SUITE 360, LAKE FOREST IL 60045
Ryan Thinh Phan officer: CSO & COO 327 CARLTON AVE, LOS GATOS CA 95032
Jannie Prestridge Herchuk director 6331 LAVENDALE AVE, DALLAS TX 75230
Winfred Parnell director 6734 TALMADGE LANE, DALLAS TX 75230
Marlene Mclennan officer: Interim Chief Financial Office 400 SOUTH AUSTRALIAN AVENUE, SUITE 800, WEST PALM BEACH FL 33401
Ruby Sharma director 24 ARNOLD DRIVE, PRINCETON JCT. NJ 08550
Robert D Auerbach director C/O THE COOPER COMPANIES, INC., SUITE 590, PLEASANTON CA 94588
Valerie Barber Palmieri director, officer: President and CEO 63 INDIAN LEDGE RD., MONROE CT 06468